Published in Eur J Clin Microbiol Infect Dis on February 12, 2016
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA (2002) 3.59
Live vaccine used to prevent the spread of varicella in children in hospital. Lancet (1974) 3.24
Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci U S A (1996) 2.71
Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J (2004) 2.69
Aging, immunity, and the varicella-zoster virus. N Engl J Med (2005) 2.20
Herpes simplex virus resistance to antiviral drugs. J Clin Virol (2003) 2.12
Varicella prevention in the United States: a review of successes and challenges. Pediatrics (2008) 1.99
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1991) 1.89
Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis (2011) 1.89
Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother (2010) 1.73
The safety profile of varicella vaccine: a 10-year review. J Infect Dis (2008) 1.50
A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008. J Gen Virol (2010) 1.49
Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics (2005) 1.47
Control of varicella: why is a two-dose schedule necessary? Pediatr Infect Dis J (2006) 1.47
Laboratory diagnosis of herpes zoster. J Clin Virol (1999) 1.32
Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis (2002) 1.22
Varicella routine vaccination and the effects on varicella epidemiology - results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011. BMC Infect Dis (2013) 1.22
A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis (2012) 1.20
Age related seroprevalence of antibodies to varicella in India. Indian Pediatr (2000) 1.18
Seroprevalence of varicella-zoster virus in the German population. Vaccine (2001) 1.14
Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. J Clin Microbiol (2006) 1.14
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr (1994) 1.12
Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med (1991) 1.11
Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis (1997) 1.11
Two-dose varicella vaccination coverage among children aged 7 years--six sentinel sites, United States, 2006-2012. MMWR Morb Mortal Wkly Rep (2014) 1.11
Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res (1996) 1.10
Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. J Infect Dis (2013) 1.10
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ (2012) 1.05
Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol (2010) 1.04
Molecular studies of Varicella zoster virus. Rev Med Virol (2006) 1.03
[Varicella vaccination in Germany. A provisional appraisal in the context of MMR vaccination]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2013) 0.99
Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods (2004) 0.99
A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid. BMC Infect Dis (2004) 0.98
Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health (2015) 0.96
Varicella in infants after implementation of the US varicella vaccination program. Pediatrics (2011) 0.95
Molecular diagnosis of zoster post varicella vaccination. J Clin Virol (2003) 0.94
The effectiveness of varicella vaccination in children in Germany: a case-control study. Pediatr Infect Dis J (2013) 0.93
A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation. J Gen Virol (2015) 0.93
Incidence of herpes zoster and its complications in Germany, 2005-2009. J Infect (2014) 0.92
Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr (2002) 0.92
Varicella vaccine and infection with varicella-zoster virus. N Engl J Med (2005) 0.91
Monitoring prevalence of varicella-zoster virus clades in Germany. Med Microbiol Immunol (2010) 0.91
The current status of live attenuated varicella vaccine. Arch Virol Suppl (2001) 0.88
Laboratory diagnosis of central nervous system infections caused by herpesviruses. J Clin Virol (2002) 0.88
Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res (2014) 0.85
Varicella and varicella vaccination in South Korea. Clin Vaccine Immunol (2014) 0.83
Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis (2001) 0.82
Resistance testing of clinical varicella-zoster virus strains. Antiviral Res (2011) 0.82
Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother (2013) 0.82
[Varicella-zoster virus infection and the serologic determination of first-infection immunity]. Dtsch Med Wochenschr (1985) 0.80
Varicella: efficacy of two-dose vaccination in childhood. Dtsch Arztebl Int (2008) 0.79
Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis (1995) 0.78
Safety of live-virus vaccines for children with immune deficiency. J Am Acad Nurse Pract (2006) 0.78
Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate. Antimicrob Agents Chemother (2015) 0.78
[Zoster. The manifestation forms in the skin, complications and therapy]. Dtsch Med Wochenschr (1997) 0.75
Management of varicella-zoster virus infections in children. Adv Exp Med Biol (1999) 0.75
Preventing congenital varicella syndrome with immunization. CMAJ (2011) 0.75